The rate of protein synthesis in hematopoietic stem cells is limited partly by 4E-BPs
The rate of protein synthesis in hematopoietic stem cells is limited partly by 4E-BPs

Robert A.J. Signer,1,2 Le Qi,1 Zhiyu Zhao,1 David Thompson,3 Alla A. Sigova,3 Zi Peng Fan,4 George N. DeMartino,3 Richard A. Young4,5 Nahum Sonenberg,6 and Sean J. Morrison1

1Howard Hughes Medical Institute, Children’s Research Institute, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA; 2Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California at San Diego, La Jolla, California 92039, USA; 3Department of Physiology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA; 4Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA; 5Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA; 6Department of Biochemistry, Goodman Cancer Centre, McGill University, Montreal, Quebec H3A 1A3, Canada

Adult stem cells must limit their rate of protein synthesis, but the underlying mechanisms remain largely unexplored. Differences in protein synthesis among hematopoietic stem cells (HSCs) and progenitor cells did not correlate with differences in proteasome activity, total RNA content, mRNA content, or cell division rate. However, adult HSCs had more hypophosphorylated eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) and 4E-BP2 as compared with most other hematopoietic progenitors. Deficiency for 4E-BP1 and 4E-BP2 significantly increased global protein synthesis in HSCs, but not in other hematopoietic progenitors, and impaired their reconstituting activity, identifying a mechanism that promotes HSC maintenance by attenuating protein synthesis.

Supplemental material is available for this article.

Received April 16, 2016; revised version accepted July 18, 2016.

[Keywords: 4E-BP, protein synthesis, stem cell]
Corresponding authors: sean.morrison@utsouthwestern.edu, rsigner@ucla.edu

Article published online ahead of print. Article and publication date are online at http://www.genesdev.org/cgi/doi/10.1101/gad.282756.116. Freely available online through the Genes & Development Open Access option.

© 2016 Signer et al. This article, published in Genes & Development, is available under a Creative Commons License (Attribution 4.0 International), as described at http://creativecommons.org/licenses/by/4.0/.

1698 GENES & DEVELOPMENT 30:1698–1703 Published by Cold Spring Harbor Laboratory Press; ISSN 0890-9369/16; www.genesdev.org
et al. 2013) or eIF4E1 (Yang et al. 2014) in neural progenitors increases protein synthesis and promotes premature neuronal differentiation.

The synthesis of O-propargyl-puromycin (OP-Puro) has facilitated the quantification of protein synthesis in individual cells in vivo (Liu et al. 2012). OP-Puro enters the acceptor site of ribosomes and is incorporated into nascent polypeptide chains. The amount of protein synthesis per hour in individual cells in vivo can then be quantified based on OP-Puro incorporation (Liu et al. 2012, Signer et al. 2014). In this study, we examined potential mechanisms that might influence differences in protein synthesis between HSCs and restricted hematopoietic progenitors in adult mouse bone marrow.

Results and Discussion

HSCs do not have high proteasome activity

We administered OP-Puro to mice, killed them 1 h later, and compared OP-Puro incorporation by subpopulations of bone marrow cells by flow cytometry. Consistent with our prior study (Signer et al. 2014), we observed significantly less OP-Puro incorporation into CD150\(^{+}\)CD48\(^{−}\)Lineage\(^{−}\)Sca-1\(^{+}\)-kit\(^{+}\)CD117\(^{−}\)CD127\(^{−}\)LSK hematopoietic progenitors (HSCs) (Kiel et al. 2005) and CD150\(^{+}\)CD48\(^{−}\)LSK multipotent progenitor cells (MPPs) (Oguro et al. 2013) as compared with restricted hematopoietic progenitors (Fig. 1A).

To test whether HSCs have high proteasome activity like embryonic stem cells (Vilchez et al. 2013), we compared the proteasome activity of HSCs versus restricted progenitors. We sorted 30,000 unfractionated bone marrow cells, CD48\(^{−}\)LSK cells [HSCs/MPPs], CD34\(^{+}\)CD16/32lowCD127\(^{−}\)Sca-1\(^{−}\)LK common myeloid progenitors (CMPs) (Akashi et al. 2000), CD34\(^{+}\)CD16/32highCD127\(^{−}\)Sca-1\(^{−}\)LK granulocyte macrophage progenitors (GMPs) (Akashi et al. 2000), Gr-1\(^{+}\) myeloid, IgM\(^{−}\)CD43\(^{−}\)B220\(^{+}\) pro-B, IgM\(^{+}\)CD43\(^{−}\)B220\(^{+}\) pre-B (Hardy et al. 1991), and B220\(^{−}\)IgM\(^{−}\) B cells. Proteasome activity in HSCs/MPPs was similar to CMPs and pro-B cells but significantly lower than unfractionated bone marrow cells, GMPs, and Gr-1\(^{+}\) cells (Fig. 1B, Supplemental Fig. S1A). Overall, proteasome activity showed little correlation with OP-Puro incorporation \(R = 0.17, P = 0.69\) (Fig. 1C).

Little correlation between protein synthesis and cell division or RNA content

We administered the thymidine analog 5-ethyl-2-deoxyuridine (EdU) to mice and measured its incorporation by HSCs and restricted progenitors in the bone marrow after 2, 6, and 12–24 h to determine the frequency of cell division in each population (Fig. 1D). We observed a reasonably linear increase in the fraction of EdU\(^{+}\) cells over time in each population (Supplemental Fig. S1BM). We observed a modest correlation between protein synthesis rates and cell division \(R = 0.42, P = 0.23\) (Fig. 1E). However, when we drove HSCs into cycle by treating them with cyclophosphamide and GCSF, we observed only a limited increase in protein synthesis [Fig. 1E]. Therefore, the rate of protein synthesis in HSCs was not determined primarily by the rate at which they divide.

To test whether protein synthesis rates reflected total RNA content [largely ribosomal RNA], we quantified total RNA by nanofluidic electrophoresis using a BioAnalyzer. HSCs had amounts of total RNA similar to those of CMPs and pro-B cells and significantly more total RNA per cell than Gr-1\(^{+}\), pre-B, and unfractionated bone marrow cells [Supplemental Fig. S1N], each of which had higher protein synthesis rates than HSCs (Fig. 1A). Therefore, we observed little correlation between...
protein synthesis rates and total RNA content per cell \( |R = 0.32, P = 0.44| \) [Supplemental Fig. S1O].

We quantified the amount of mRNA per cell by RNA sequencing [RNA-seq] after adding RNA standards that allow normalization of transcript numbers to cell number [Fig. 1F, Loven et al. 2012]. On average, HSCs had significantly more mRNA per cell as compared with pre-B cells, unfractionated bone marrow, and Gr-1\(^-\) cells but less mRNA per cell than CMPs, GMPs, and pro-B cells [Fig. 1G], all of which had higher protein synthesis rates than HSCs [Fig. 1A]. Therefore, we observed little correlation between protein synthesis rates and mRNA content in hematopoietic cells \( |R = 0.48, P = 0.28| \) [Fig. 1H].

**HSCs have relatively high levels of hypophosphorylated 4E-BPs**

We assessed the levels of total, phosphorylated, and nonphosphorylated 4E-BP1 and 4E-BP2 in 30,000 sorted cells from each population [Fig. 2A]. Control experiments using peripheral blood from 4E-BP1\(^-/-\) [Tsukiyama-Kohara et al. 2001], 4E-BP2\(^-/-\) [Banko et al. 2005], and 4E-BP1\(^-/-\); 4E-BP2\(^-/-\) mice [Le Bacquer et al. 2007] showed that the upper band was 4E-BP1, and the lower band was 4E-BP2 [Supplemental Fig. S2A,B]. HSCs/MPPs expressed relatively high levels of total 4E-BP1 and 4E-BP2 as compared with most hematopoietic progenitors—significantly higher than Gr-1\(^-\), pro-B, pre-B, and IgM\(^+\) B cells [Fig. 2A–C]. Levels of nonphosphorylated 4E-BP1 and 4E-BP2 were also significantly higher in HSCs/MPPs as compared with Gr-1\(^-\), pro-B, pre-B, and IgM\(^+\) B cells [Fig. 2D,E]. The ratio of phosphorylated to total 4E-BP1/2 tended to be lower in HSCs as compared with restricted progenitors [Supplemental Fig. S2C,D]. Differences in \( \beta \)-actin levels among cell populations represented differences in the amount of \( \beta \)-actin per cell, as lysates from equal numbers of cells were used in these experiments [Fig. 2A]. Nonetheless, even when levels of total and nonphosphorylated 4E-BP1 and 4E-BP2 were normalized to differences in \( \beta \)-actin, they tended to remain higher in HSCs/MPPs as compared with Gr-1\(^-\), pro-B, pre-B, and IgM\(^+\) B cells [although not all of the differences were statistically significant] [Supplemental Fig. S2E–H].

Levels of phosphorylated S6 strongly correlated with levels of phosphorylated 4E-BP1 \( |R = 0.88, P = 0.004| \) [Fig. 2F] or phosphorylated 4E-BP2 \( |R = 0.95, P = 0.0003| \) [Fig. 2G]. However, correlations between phosphorylated Akt and phosphorylated 4E-BP1 \( |R = 0.56, P = 0.015| \) [Fig. 2H] or phosphorylated 4E-BP2 \( |R = 0.50, P = 0.021| \) [Fig. 2I] were weaker. These data suggest that differences in 4E-BP phosphorylation among HSCs and progenitor cells likely reflect differences in mTORC1 signaling. Levels of phosphorylated 4E-BP1 \( |R = 0.73, P = 0.06| \) [Fig. 2J] and phosphorylated 4E-BP2 \( |R = 0.57, P = 0.018| \) [Fig. 2K] normalized to \( \beta \)-actin exhibited stronger correlations with protein synthesis rates than any other parameter that we tested. Levels of phosphorylated 4E-BP1 \( |R = 0.40, P = 0.037| \) [Supplemental Fig. S2I] and phosphorylated 4E-BP2 \( |R = 0.24, P = 0.06| \) [Supplemental Fig. S2J] that were normalized based on cell numbers did not exhibit as strong a correlation with protein synthesis.

To test whether 4E-BPs limit the rate of protein synthesis in HSCs, we examined OP-Puro incorporation by HSCs and progenitors in 4E-BP1\(^-/-\); 4E-BP2\(^-/-\), and 4E-BP1\(^-/-\); 4E-BP2\(^-/-\) mice. 4E-BP1\(^-/-\) or 4E-BP2\(^-/-\) HSCs did not exhibit significant changes in OP-Puro incorporation compared with wild-type HSCs [Fig. 3A]. However, 4E-BP1\(^-/-\); 4E-BP2\(^-/-\) HSCs exhibited a significant increase in protein synthesis as compared with wild-type HSCs [23\%, \( P < 0.05| \) Fig. 3A]. The magnitude of this increase was close to that observed after Pten deletion, which leads to HSC depletion [Signer et al. 2014]. We did not detect a statistically significant effect of 4E-BP1 deficiency, 4E-BP2 deficiency, or combined 4E-BP1/4E-BP2 deficiency on the rate of protein synthesis in other hematopoietic progenitors [Fig. 3B]. HSCs thus appear to be more sensitive to the effects of 4E-BP1/2 on global protein synthesis.
4E-BP hypophosphorylation in HSCs

4E-BP1/2-deficient mice have HSCs with increased protein synthesis but largely normal hematopoiesis. (A) Mean OP-Puro incorporation by HSCs from 4E-BP1−/−, 4E-BP2−/−, 4E-BP1−/−;4E-BP2−/−, or wild-type mice. n = 9 mice per genotype in nine experiments. The value relative to wild type is shown above each bar. (B) Mean OP-Puro incorporation into each restricted progenitor population from the same mice as in A. (C–E) Number of white blood cells (WBC), red blood cells (RBC), and platelets (PLT) in the peripheral blood. (F) Cell number in the bone marrow (BM, one femur and one tibia), spleen (SPL), and thymus (Thy). (G–I) Frequencies of MPPs, CMPs, GMPs, and megakaryocyte erythroid-restricted progenitors [MEPs] (H), Gr−1− myeloid and Ter119+ erythroid cells [I], and pro-B, pre-B, and IgM+ B cells [I] in the bone marrow. (J) Frequencies of CD4+ and CD8+ T cells in the spleen. (K) Frequency of HSCs in the bone marrow. n = 6 mice per genotype in three experiments in C–K. (L) Frequency of BrdU+ HSCs after a 72-h pulse of BrdU in vivo. (M) Frequency of annexin V+ HSCs. n = 5–6 mice per genotype in four experiments in L and M. All data represent mean ± SD. The statistical significance of differences relative to wild type was assessed using one-way ANOVAs (repeated-measures in some cases). *P < 0.05; **P < 0.01; ***P < 0.001.

Figure 3. 4E-BP1/2-deficient mice have HSCs with impaired regenerative activity

4E-BP1−/−, 4E-BP2−/−, and 4E-BP1−/−;4E-BP2−/− compound mutant mice all exhibited relatively normal hematopoiesis (Fig. 3C–J). HSC frequency appeared to be higher in 4E-BP2−/− (65% ± 32%, P < 0.05) [Fig. 3K] and 4E-BP1−/−;4E-BP2−/− (80% ± 53%, P < 0.01) mutant mice [Fig. 3K] as compared with controls. This modest increase in HSC frequency was not associated with significant changes in the frequency of dividing [Fig. 3L] or dying [Fig. 3M] HSCs. This suggests that the increase in HSC frequency may have been caused by a lower rate of differentiation by 4E-BP1/2-deficient HSCs. We also observed modest but significant declines in the frequencies of CMPs, Ter119+ erythroid progenitors, and pro-B cells in the bone marrow of some 4E-BP-deficient mice as compared with controls [Fig. 3G–I].

To test the effect of 4E-BP deficiency on HSC function, we performed competitive reconstitution assays in irradiated mice. Bone marrow cells (5 × 10⁵ cells) from 4E-BP1−/−, 4E-BP2−/−, 4E-BP1−/−;4E-BP2−/−, or wild-type mice [all CD45.2+ were transplanted with equal numbers of wild-type recipient bone marrow cells [CD45.1+] into irradiated mice [CD45.1+]. Recipients of 4E-BP-deficient bone marrow cells had significantly higher levels of donor-derived hematopoietic cells in their blood 4–16 wk after transplantation [Fig. 4A–D]. To test whether this increased reconstitution reflected increased HSC frequency in the bone marrow of 4E-BP-deficient donors [Fig. 3K] or increased function of 4E-BP-deficient HSCs, we competitively transplanted 10 CD150+CD48−LSK HSCs from 4E-BP1−/−;4E-BP2−/− or wild-type donors into irradiated recipient mice along with recipient bone marrow cells. 4E-BP-deficient HSCs gave normal levels of donor cell reconstitution [Fig. 4E–H]. The higher level of donor cell reconstitution by 4E-BP-deficient bone marrow cells
thus reflects higher HSC frequency in the donor bone marrow rather than increased reconstituting activity by 4E-BP-deficient HSCs.

Although 4E-BP2−/− and 4E-BP1−/−;4E-BP2−/− mutant mice had increased HSC frequency in their bone marrow as compared with controls (Fig. 3K), the frequency of donor HSCs in primary recipient mice after bone marrow transplantation did not significantly differ between recipients of 4E-BP-deficient cells as compared with control cells [Supplemental Fig. S3B]. These data raised the possibility that 4E-BP deficiency may impair HSC self-renewal after transplantation.

To assess HSC self-renewal potential, we performed secondary transplants of 5 × 10^6 bone marrow cells from primary recipient mice with levels of donor cell reconstitution nearest the median values in each treatment. Deficiency for only 4E-BP1 or 4E-BP2 did not significantly affect donor cell reconstitution in secondary recipient mice as compared with control cells. In contrast, secondary recipients of 4E-BP1−/−;4E-BP2−/− cells had significantly less donor cell reconstitution in all lineages 16 wk after transplantation as compared with secondary recipients of wild-type donor cells [Fig. 4I–L]. Nonetheless, other mechanisms must also limit protein synthesis in HSCs, as protein synthesis rates in 4E-BP1−/−;4E-BP2−/− HSCs remained significantly lower than in 4E-BP1−/−;4E-BP2−/− restricted hematopoietic progenitors. Moreover, both GMPs and megakaryocyte erythroid-restricted progenitors (MEPs) had higher levels of hypophosphorylated 4E-BPs relative to control HSCs (Supplemental Fig. 2D,E) and yet still had higher levels of global protein synthesis [Fig. 1A], perhaps because global protein synthesis in these cells is not as sensitive to 4E-BP1/2 as in HSCs [Fig. 3B].

Materials and methods

Mice

Eif4ebp1−/− [Tsukiyama-Kohara et al. 2001], Eif4ebp2−/− [Banko et al. 2005], and Eif4ebp1−/−;Eif4ebp2−/− [Le Bacquer et al. 2007] mice have been described previously. These mice were backcrossed for at least 10 generations onto a C57BL/6J background. C57BL/Ka-Thy-1.1 [CD45.2] mice were used as wild type throughout this study. C57BL/Ka-Thy-1.2 [CD45.1] mice were used as transplant recipients. Male and female mice between 8 and 14 wk old were used in all studies. Cyclophosphamide and GCSF were administered as described (Signer et al. 2014). All mice were housed in the Animal Resource Center at the University of Texas Southwestern Medical Center, and all protocols were approved by the University of Texas Southwestern Medical Center Institutional Animal Care and Use Committee.

Proteasome activity assay

Proteasome activity was determined by measuring the rate of hydrolysis of Suc-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin (AMC). This substrate is specific for the proteasome under the assay conditions used here and is hydrolyzed by all proteasome holoenzymes. The activity reported by this assay represents the total enzymatic capacity of the cellular proteasome and is typically dominated by the 26S proteasome [Sasai et al. 1984; Demartino and Gillette 2007]. From each population, 3 × 10^6 cells were double-sorted into 96-well black plates. One-hundred microliters of buffer containing 20 mM Tris-HCl (pH 7.6), 1 mM 2-mercaptoethanol, 5 mM MgCl2, 1 mM ATP, and 0.4% NP-40 was added to each well followed immediately by 50 μL of 200 μM Suc-Leu-Leu-Val-Tyr-AMC (Bachem). The fluorescence of free AMC generated by proteasomal hydrolysis of the substrate was monitored continuously (one read per minute for 180 min at 37°C) at 360/460 nm using a BioTek Synergy II plate reader. Controls included reactions conducted in the absence of cells, in the presence of 10 mM MG132 (UBPr60), or using purified bovine 26S proteasome instead of cells. Data are expressed as arbitrary fluorescent units per well.

The rate of cell division

Two milligrams of EdU (Thermo Scientific) in PBS was injected intraperitoneally per mouse every 6 h. Mice were analyzed 2, 6, 12, and 24 h after EdU administration. These short labeling times minimized the extent to which results were affected by the entry of labeled cells into each population through the maturation of upstream progenitors, the exit of labeled cells through differentiation into downstream progeny, or saturation of labels in rapidly dividing cell populations. Bone marrow cells (3 × 10^6 cells) were stained with antibodies as described in the Supplemental Material. Cells were fixed and permeabilized, and the azide-alkyne cycloaddition was performed as with OP-Puro detection and analyzed by flow cytometry. For cyclophosphamide- and GCSF-treated mice, BrdU was administered in place of EdU and was detected with the BrdU flow kit.

Acknowledgments

We thank K. Cornell, N. Loof, and the Moody Foundation Flow Cytometry Facility. S.J.M. is a Howard Hughes Medical Institute Investigator, the Mary McDermott Cook Chair in Pediatric Genetics, the Kathryn and Gene Bishop Distinguished Chair in Pediatric Research, and the director of the Hamon Laboratory for Stem Cells and Cancer. L.Q. is supported by a fellowship from the Howard Hughes Medical Institute. This work was supported by the National Institutes of Health [National Institute of Diabetes and Digestive and Kidney Diseases R01 DK100848] and the Cancer Prevention and Research Institute of Texas.

References


The rate of protein synthesis in hematopoietic stem cells is limited partly by 4E-BPs


*Genes Dev.* 2016 30: 1698-1703 originally published online August 4, 2016
Access the most recent version at doi:10.1101/gad.282756.116

---

**Supplemental Material**

http://genesdev.cshlp.org/content/suppl/2016/08/04/gad.282756.116.DC1.html

**References**

This article cites 34 articles, 8 of which can be accessed free at:
http://genesdev.cshlp.org/content/30/15/1698.full.html#ref-list-1

**Open Access**

Freely available online through the *Genes & Development* Open Access option.

**Creative Commons License**

This article, published in *Genes & Development*, is available under a Creative Commons License (Attribution 4.0 International), as described at http://creativecommons.org/licenses/by/4.0/.

**Email Alerting Service**

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or click here.

---

To subscribe to *Genes & Development* go to:
http://genesdev.cshlp.org/subscriptions

© 2016 Signer et al.; Published by Cold Spring Harbor Laboratory Press